Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies

John N. Allan, MD, Krish Patel, MD, Anthony R. Mato, MDMSCE, William G. Wierda, MD PhD, Javier Pinilla Ibarz, MD PhD, Michael Y. Choi, MD, Susan M. O'Brien, MD, Jeff P. Sharman, MD, Mazyar Shadman, MD, Douglas E Gladstone, MD, Matthew S. Davids, MD, John M. Pagel, MD PhD DSc, Renee Ward, MD PhD, Gary Acton, MD, Pietro Taverna, PhD, Judith A. Fox, PhD, Richard R. Furman, MD, Jennifer R. Brown, MD PhD

Blood (2019) 134 (Supplement_1): 3041.

https://doi.org/10.1182/blood-2019-126286

Published: 2019

Journal Articles

Preliminary Safety, Pharmacokinetic, and Pharmacodynamic Results from a Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton's Tyrosine Kinase Inhibitor (BTKi), Vecabrutinib, in B-Lymphoid Malignancies

John N. Allan, MD, William G. Wierda, MD PhD, Krish Patel, MD, Susan M. O'Brien, MD, Anthony R Mato, MD, Matthew S Davids, Richard R. Furman, MD, John M. Pagel, MD PhD, Judith A. Fox, PhD, Renee Ward, MD PhD, Pietro Taverna, PhD, Jennifer R. Brown, MD PhD

Blood (2018) 132 (Supplement 1): 3141.

https://doi.org/10.1182/blood-2018-99-116382

Published: 2018

Journal Articles

AMV564, a Bivalent Bispecific (2×2) CD33/CD3 T-Cell Engager, Is Active and Improves Survival in a Mouse Model of Acute Myeloid Leukemia

Linda G Eissenberg, PhD, Julie Ritchey, Michael P. Rettig, PhD, Judith A. Fox, PhD, Jeanmarie Guenot, PhD, John F. DiPersio, MD PhD

Blood (2018) 132 (Supplement 1): 2727.

https://doi.org/10.1182/blood-2018-99-118573

Published: 2018

Journal Articles

High Prevalence of BTK Mutations on Ibrutinib Therapy after 3 Years of Treatment in a Real-Life Cohort of CLL Patients: A Study from the French Innovative Leukemia Organization (FILO) Group

Anne Quinquenel, Luc Matthieu Fornecker, Remi Letestu, Carole Fleury, Loic Ysebaert, MD PhD, Marie-Sarah Dilhuydy, MD, Romain Guieze, MD, Pierre Feugier, Damien Roos-Weil, MD, Lise Willems, MD, Anne-Sophie Michallet, MD PhD, Alain Jacques Delmer, MD, Pietro Taverna, PhD, Judith A. Fox, PhD, Vincent Levy, MD PhD, Florence Cymbalista, MD, Fanny Baran-Marszak, MD PhD

Blood (2018) 132 (Supplement 1): 584.

https://doi.org/10.1182/blood-2018-99-114027

Published: 2018

Journal Articles

Vecabrutinib Is Efficacious In Vivo in a Preclinical CLL Adoptive Transfer Model

Billy Michael Chelliah Jebaraj, PhD, Annika Scheffold, PhD, Eugen Tausch, MD, Judith A. Fox, PhD, Pietro Taverna, PhD, Stephan Stilgenbauer

Blood (2018) 132 (Supplement 1): 1868.

https://doi.org/10.1182/blood-2018-99-116664

Published: 2018

Journal Articles

First-in-Human Phase 1a Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitor SNS-062 in Healthy Subjects

Linda L. Neuman, MD MBA, Renee Ward, MD PhD, David Arnold, Daniel L. Combs, BS, Deena Gruver, MS, Wendy Hill, MBA, Josué Mfopou Kunjom, MD PhD, Langdon L. Miller, MD, Judith A. Fox, PhD

Blood (2016) 128 (22): 2032.

https://doi.org/10.1182/blood.V128.22.2032.2032

Published: 2016

Journal Articles

Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR)

Blood (2014) 124 (21): LBA-6.

https://doi.org/10.1182/blood.V124.21.LBA-6.LBA-6

Published: 2014

NARROW

Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies

Preliminary Safety, Pharmacokinetic, and Pharmacodynamic Results from a Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton's Tyrosine Kinase Inhibitor (BTKi), Vecabrutinib, in B-Lymphoid Malignancies

AMV564, a Bivalent Bispecific (2×2) CD33/CD3 T-Cell Engager, Is Active and Improves Survival in a Mouse Model of Acute Myeloid Leukemia

High Prevalence of BTK Mutations on Ibrutinib Therapy after 3 Years of Treatment in a Real-Life Cohort of CLL Patients: A Study from the French Innovative Leukemia Organization (FILO) Group

Vecabrutinib Is Efficacious In Vivo in a Preclinical CLL Adoptive Transfer Model

First-in-Human Phase 1a Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitor SNS-062 in Healthy Subjects

Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR)

Email alerts

ASH Publications

American Society of Hematology

Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies

Preliminary Safety, Pharmacokinetic, and Pharmacodynamic Results from a Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton's Tyrosine Kinase Inhibitor (BTKi), Vecabrutinib, in B-Lymphoid Malignancies

AMV564, a Bivalent Bispecific (2×2) CD33/CD3 T-Cell Engager, Is Active and Improves Survival in a Mouse Model of Acute Myeloid Leukemia

High Prevalence of BTK Mutations on Ibrutinib Therapy after 3 Years of Treatment in a Real-Life Cohort of CLL Patients: A Study from the French Innovative Leukemia Organization (FILO) Group

Vecabrutinib Is Efficacious In Vivo in a Preclinical CLL Adoptive Transfer Model

First-in-Human Phase 1a Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitor SNS-062 in Healthy Subjects

Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only